Butyroyloxymethyl-4-phenylbutyrate (AN-113) is a novel HDACI that releases potent anti-neoplastic derivatives upon intracellular hydrolysis. The precursor of AN-113, 4-phenylbutyrate has shown promising results in a Phase I study of gliomas, and we hypothesized that AN-113 offers significant advantages over the parent drug. AN-113 demonstrates selective in vitro cytotoxicity against malignant cells while sparing normal astrocytes, effective at doses over 20-fold lower than 4-phenylbutyrate. Combining AN-113 and radiation results in additive therapeutic effects. Enthusiasm is lent to this approach by the ability of AN-113 to efficiently kill glioma cells, its bioavailability and potency when administered orally, its capacity to cross the blood-brain barrier, and its effectiveness in combination with radiation.
Bibliographical noteFunding Information:
This research was supported in part by the “Marcus Center for Pharmaceutical and Medicinal Chemistry” at Bar Ilan University, NIH-PO1 NS-42927-27A2 (D.A.H.-K., K.R.L.), NIH Brain Tumor SPORE Grant P50 CA097257 (D.A.H.-K., K.R.L.), The Nancy and Stephen Grand Philanthropic Fund, the Thrasher Research Fund, and the Israel Science Foundation Grant 542/00-4 (A.R. and A.N.).
- HDAC inhibitor
- Radiation potentiation